 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Too Much Thyroid Hormone Increases Risk for Bone Fractures
3 April 2001 | Volume 134 Issue 7 | Page S85
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Risk for Fracture in Women with Low Serum Levels of Thyroid-Stimulating Hormone." It is in the 3 April 2001 issue of Annals of Internal Medicine (volume 134, pages 561-568). The authors are DC Bauer, B Ettinger, MC Nevitt, and KL Stone, for the Study of Osteoporotic Fractures Research Group.
What is the problem and what is known about it so far?
As people get older, their bones lose calcium and become less dense. When this bone thinning becomes severe, it is called osteoporosis. Persons with osteoporosis are at high risk for broken bones (fractures). Many older women have osteoporosis. Some older women also have problems with the thyroid gland, a gland located in the neck that makes thyroid hormone. Thyroid hormone is important in regulating the body's metabolism, particularly its use of energy, fats, and protein. Several past studies have examined whether high levels of thyroid hormone lead to osteoporosis. Results of these studies have been confusing, and few have looked at whether women with high levels of thyroid hormone actually have more fractures than women with normal thyroid hormone levels.
Why did the researchers do this particular study?
To see whether women with high thyroid hormone levels are more likely than women with normal thyroid hormone levels to have bone fractures.
Who was studied?
The study included 686 white women older than 65 years of age who were recruited from medical centers in four U.S. cities.
How was the study done?
The researchers took spine x-rays and measured thyroid-stimulating hormone (TSH) levels in all women as they entered the study. Thyroid-stimulating hormone is an indirect way of measuring actual thyroid hormone; TSH levels are low when thyroid hormone levels are high. The researchers then contacted the women by mail every 4 months for 4 years to ask whether they had had a bone fracture since the last mailing. Because many spine fractures go undiagnosed, the researchers confirmed each woman's report of a fracture by getting copies of x-rays or written x-ray reports. After 4 years, the women had another set of spine x-rays. The researchers then compared the frequency of fractures in women with and without high thyroid hormone levels (as suggested by low TSH levels).
What did the researchers find?
During the 4 years of the study, 48% of the women had a hip fracture and 56% had a spine fracture. Women whose TSH level indicated a high thyroid hormone level were three times more likely to have a hip fracture and four times more likely to have a spine fracture than were women with normal levels of TSH.
What were the limitations of the study?
Thyroid function was measured indirectly by looking at TSH levels. Measurement of thyroid hormone might provide more information about risk for fracture. Also, the study included only white women.
What are the implications of the study?
Too much thyroid hormone may put older women at risk for bone fractures. Women with abnormal thyroid function may benefit from close monitoring to ensure that their thyroid hormone levels are kept in the normal range.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  N. Rodondi, D. C. Bauer, A. R. Cappola, J. Cornuz, J. Robbins, L. P. Fried, P. W. Ladenson, E. Vittinghoff, J. S. Gottdiener, and A. B. Newman Subclinical Thyroid Dysfunction, Cardiac Function, and the Risk of Heart Failure: The Cardiovascular Health Study J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1152 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A Heemstra, W. M van der Deure, R. P Peeters, N. A Hamdy, M. P Stokkel, E. P Corssmit, J. A Romijn, T. J Visser, and J. W Smit Thyroid hormone independent associations between serum TSH levels and indicators of bone turnover in cured patients with differentiated thyroid carcinoma. Eur. J. Endocrinol., July 1, 2008; 159(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sun, S. Vukicevic, R. Baliram, G. Yang, R. Sendak, J. McPherson, L.-L. Zhu, J. Iqbal, R. Latif, A. Natrajan, et al. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss PNAS, March 18, 2008; 105(11): 4289 - 4294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. D. Bassett, A. J. Williams, E. Murphy, A. Boyde, P. G. T. Howell, R. Swinhoe, M. Archanco, F. Flamant, J. Samarut, S. Costagliola, et al. A Lack of Thyroid Hormones Rather than Excess Thyrotropin Causes Abnormal Skeletal Development in Hypothyroidism Mol. Endocrinol., February 1, 2008; 22(2): 501 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. D. Bassett, K. Nordstrom, A. Boyde, P. G. T. Howell, S. Kelly, B. Vennstrom, and G. R. Williams Thyroid Status during Skeletal Development Determines Adult Bone Structure and Mineralization Mol. Endocrinol., August 1, 2007; 21(8): 1893 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Lata and M. E. Elliott Patient Assessment in the Diagnosis, Prevention, and Treatment of Osteoporosis Nutr Clin Pract, June 1, 2007; 22(3): 261 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. D. Bassett, P. J. O'Shea, S. Sriskantharajah, B. Rabier, A. Boyde, P. G. T. Howell, R. E. Weiss, J.-P. Roux, L. Malaval, P. Clement-Lacroix, et al. Thyroid Hormone Excess Rather Than Thyrotropin Deficiency Induces Osteoporosis in Hyperthyroidism Mol. Endocrinol., May 1, 2007; 21(5): 1095 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Cooper Approach to the Patient with Subclinical Hyperthyroidism J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 3 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hase, T. Ando, L. Eldeiry, A. Brebene, Y. Peng, L. Liu, H. Amano, T. F. Davies, L. Sun, M. Zaidi, et al. TNF{alpha} mediates the skeletal effects of thyroid-stimulating hormone PNAS, August 22, 2006; 103(34): 12849 - 12854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Boelaert and J A Franklyn Thyroid hormone in health and disease J. Endocrinol., October 1, 2005; 187(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Surks, G. Goswami, and G. H. Daniels The Thyrotropin Reference Range Should Remain Unchanged J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5489 - 5496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A C. Heijckmann, M. S P Huijberts, P. Geusens, J. de Vries, P. P C A Menheere, and B. H R Wolffenbuttel Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma Eur. J. Endocrinol., July 1, 2005; 153(1): 23 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Biondi, E. A. Palmieri, M. Klain, M. Schlumberger, S. Filetti, and G. Lombardi Subclinical hyperthyroidism: clinical features and treatment options Eur. J. Endocrinol., January 1, 2005; 152(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E H Hoogendoorn, M den Heijer, A P J van Dijk, and A R Hermus Subclinical hyperthyroidism: to treat or not to treat? Postgrad. Med. J., July 1, 2004; 80(945): 394 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Helfand Screening for Subclinical Thyroid Dysfunction in Nonpregnant Adults: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, January 20, 2004; 140(2): 128 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Surks, E. Ortiz, G. H. Daniels, C. T. Sawin, N. F. Col, R. H. Cobin, J. A. Franklyn, J. M. Hershman, K. D. Burman, M. A. Denke, et al. Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management JAMA, January 14, 2004; 291(2): 228 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Stevens, C. B. Harvey, A. J. Scott, P. J. O'Shea, J. C. Barnard, A. J. Williams, G. Brady, J. Samarut, O. Chassande, and G. R. Williams Thyroid Hormone Activates Fibroblast Growth Factor Receptor-1 in Bone Mol. Endocrinol., September 1, 2003; 17(9): 1751 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Wemeau, P. Caron, C. Schvartz, J.-L. Schlienger, J. Orgiazzi, C. Cousty, and V. Vlaeminck-Guillem Effects of Thyroid-Stimulating Hormone Suppression with Levothyroxine in Reducing the Volume of Solitary Thyroid Nodules and Improving Extranodular Nonpalpable Changes: A Randomized, Double-Blind, Placebo-Controlled Trial by the French Thyroid Research Group J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4928 - 4934. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
